American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Celldex Therapeutics, Inc. (CLDX)

$29.25 +0.97% NASDAQ: CLDX · 15-min delayed

HAMPTON, New Jersey
Public · NASDAQ: CLDX
198 employees

Visit website Follow

$2.8BMarket cap

$1.5MRevenue · FY2025

-$258.8MNet income

198Employees

CLDXNASDAQ

1986IPO

About Celldex Therapeutics, Inc.

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: CLDX
Employees: 198
IPO date: May 15, 1986
Headquarters: 53 FRONTAGE ROAD
HAMPTON, New Jersey 08827
Phone: 908-200-7500
Industry: Medical Devices
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 529900F018DMYWH38923

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: CLDX Nasdaq
SEC CIK: 744218
LEI: 529900F018DMYWH38923
EIN: 133191702
SIC: 2835 IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Celldex Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/celldex-therapeutics-inc/"><img src="https://americancompanies.com/badge/celldex-therapeutics-inc.svg" alt="Celldex Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Celldex Therapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $1.5M
Net income: -$258.8M
Total assets: $583.0M
Market cap: $2.8B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: CLDX

$29.25 +0.97%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$22.58 $44.87

52-week range

Market cap: $2.8B
Shares outstanding: 94.7M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: May 15, 1986

Celldex Therapeutics, Inc. (CLDX) Stock Price

Reported a net loss of $258.8M in FY2025.
Trading 35% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Celldex Therapeutics, Inc..

Write a review

Newsroom

News about Celldex Therapeutics, Inc.

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte Zacks Investment Research · 2026-09-23 · neutral Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting GlobeNewswire Inc. · 2026-06-14 · positive Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting GlobeNewswire Inc. · 2026-06-14 · positive Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire Inc. · 2026-04-06 · positive Celldex Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. · 2026-04-02 · positive Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 GlobeNewswire Inc. · 2026-03-01 · positive

News & sentiment via Polygon.io

FAQ

Celldex Therapeutics, Inc.: frequently asked questions

Is Celldex Therapeutics, Inc. an American company?

Celldex Therapeutics, Inc. is a US-based company headquartered in Hampton, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Celldex Therapeutics, Inc. headquartered?

Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey, United States.

Is Celldex Therapeutics, Inc. publicly traded?

Yes — Celldex Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol CLDX on the NASDAQ.

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics, Inc. is an American Medical Devices company in the Health & Beauty sector.

Explore